NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Dr. Matthias...
Every successful drug was once in Phase I.
"In previously published non-controlled studies, ibogaine has demonstrated rapid and sustained efficacy in treating OUD and has the...
"Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in...
